Compare POM & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POM | CLGN |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.2M |
| IPO Year | 2021 | 2015 |
| Metric | POM | CLGN |
|---|---|---|
| Price | $1.80 | $3.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 40.1K |
| Earning Date | 11-10-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.26 |
| 52 Week High | $6.43 | $4.78 |
| Indicator | POM | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.68 | 57.00 |
| Support Level | $0.28 | $0.34 |
| Resistance Level | $1.78 | $3.91 |
| Average True Range (ATR) | 0.46 | 0.35 |
| MACD | 0.08 | -0.06 |
| Stochastic Oscillator | 48.35 | 45.19 |
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.